Seven Eight Capital LP Buys Shares of 4,585 Natera, Inc. (NASDAQ:NTRA)

Seven Eight Capital LP purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,585 shares of the medical research company’s stock, valued at approximately $497,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC raised its position in shares of Natera by 16.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 11,009 shares of the medical research company’s stock worth $1,189,000 after purchasing an additional 1,518 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Natera by 6.0% in the second quarter. Amalgamated Bank now owns 7,590 shares of the medical research company’s stock worth $822,000 after acquiring an additional 428 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Natera in the second quarter valued at $767,000. SYSTM Wealth Solutions LLC lifted its position in shares of Natera by 3,592.9% in the second quarter. SYSTM Wealth Solutions LLC now owns 12,519 shares of the medical research company’s stock valued at $1,356,000 after acquiring an additional 12,180 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in shares of Natera by 105.1% during the second quarter. E Fund Management Co. Ltd. now owns 9,979 shares of the medical research company’s stock valued at $1,081,000 after acquiring an additional 5,113 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Up 0.5 %

Shares of NASDAQ:NTRA opened at $127.78 on Monday. The stock has a 50-day simple moving average of $114.45 and a 200-day simple moving average of $105.54. The stock has a market capitalization of $15.69 billion, a P/E ratio of -40.96 and a beta of 1.53. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $132.01. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period in the previous year, the firm earned ($0.97) earnings per share. Natera’s revenue for the quarter was up 58.1% on a year-over-year basis. Equities analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of recent research reports. TD Cowen upped their target price on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. BTIG Research lifted their target price on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Stephens reissued an “overweight” rating and set a $125.00 price target on shares of Natera in a research note on Friday, August 9th. Finally, Robert W. Baird lifted their price objective on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $120.07.

Insider Activity at Natera

In other news, insider Daniel Rabinowitz sold 1,057 shares of the company’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the completion of the sale, the insider now owns 206,400 shares of the company’s stock, valued at $21,211,728. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Daniel Rabinowitz sold 1,057 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the sale, the insider now directly owns 206,400 shares in the company, valued at approximately $21,211,728. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 37,500 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $108.10, for a total value of $4,053,750.00. Following the completion of the transaction, the chief executive officer now owns 213,351 shares of the company’s stock, valued at approximately $23,063,243.10. The disclosure for this sale can be found here. In the last three months, insiders sold 93,921 shares of company stock worth $10,551,281. Corporate insiders own 7.60% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.